WELCOME TO EVERYBODY ON THE
BOARD, WELCOME TO Dr.
BERTAGNOLLI.
IT'S A PLEASURE TO HAVE YOU
JOINING US THIS MORNING.
I JUST WANT TO REMIND EVERYBODY
ON THE BOARD THIS IS AN OPEN
SESSION THAT WE ARE NOW CALLING
TO ORDER.
I ALSO WANT TO NOTE THAT MEMBERS
OF THE PUBLIC, WHO MAY WISH TO
EXPRESS VIEWS REGARDING ANY
ITEMS DISCUSSED DURING THIS
MEETING, MAY DO SO BY WRITING TO
Dr. TONDRAVI EXECUTIVE
SECRETARY WITHIN 10 DAYS OF THE
MEETING.
ANY WRITTEN STATEMENTS BY
MEMBERS OF THE PUBLIC WILL
RECEIVE CAREFUL CONSIDERATION
AND WE'LL LIKE TO TURN THE FLOOR
OVER TO Dr. MONICA
BERTAGNOLLI.
>>Dr. Bertagnolli: THANK YOU SO
MUCH, ERIC.
CAN I HAVE THE FIRST SLIDE,
PLEASE.
SO, I'M REALLY PLEASED TO BE
HERE TO SPEAK TO YOU TODAY.
THIS IS MY VERY FIRST BSE
MIGHTING AS NCI DIRECTOR.
THE INTRAMURAL RESEARCH PROGRAM
IS SUCH A CRITICAL PART OF NCI'S
MISSION.
I HAVE TO EXPRESS MY GRATITUDE
TO ALL OF YOU THAT WE ARE ABLE
TO TAP INTO YOUR EXPERTISE TO
HELP ENSURE OUR INTRAMURAL
RESEARCH IS ON THE RIGHT PATH.
>>Dr. BERTAGNOLLI.
YOU ARE CUT NO CU CUTTING IN AN.
>>YOU ARE FINE.
WE HEAR YOU FINE.
>>SOUNDS GOOD TO ME.
>>SHE'S NOT CUT NORTH AND OUT
FOR US.
>>I'M SORRY, MY APOLOGIES.
>>Dr. Bertagnolli: GREAT.
YOU KNOW, I KNOW WE HAVE A LOT
TO COVER TODAY SO I'M GOING TO
TRY TO BE QUICK.
I'M GOING TO TALK A LITTLE BIT
ABOUT RECENT PROGRESS, OUR
BUDGET, GIVE YOU A QUICK VIEW OR
EARLY VIEW OF SOMETHING WE'RE
CALLING THE NATIONAL CANCER PLAN
AND SOME OVER ALL UPDATES.
>>PRESIDENT BIDEN CONTINUED IN
HIS STATE OF THE UNION ADDRESS,
TO SHOW STRONG SUPPORT FOR ALL
THAT WE SEEK TO DO.
YOU MAY HAVE SEEN HE CONTINUED
HIS MESSAGE THAT INTENDS TO GO
BIG TO ACHIEVE BOLD GOALS,
WORTHY OF COMPARISON TO THE
MOONSHOT EFFORT THAT GOT US TO
THE MOON IN 1969.
HE CALLED UPON ALL US OF TO WORK
TOGETHER TO END CANCER AS WE
KNOW IT, TO CUT THE CANCER
MORTALITY RATE BY 50% IN 25
YEARS, TO TURN MORE CANCERS FROM
DEATH SENTENCES INTO TREATABLE
DISEASES AND TO PROVIDE MORE
SUPPORT FOR PATIENTS AND
FAMILIES.
HIS SPEECH WAS VERY TOUCHING.
HE CLEARLY MADE IT ALL OF US
AWARE THAT OUR FOCUS IS CANCER
PATIENTS AND THEIR FAMILIES.
AND WE CAN NEVER FORGET THAT
THIS IS OUR CORE MISSION.
HAVING PRESIDENT JOE BIDEN
BEHIND US, WE'RE VERY OPTIMISTIC
AND NCI OVER THAT YOU WILL NOW
IS OUR TIME TO MAKE VERY BIG
MOVES AND BIG PROGRESS.
NEXT SLIDE, PLEASE.
WE GOT GOOD NEWS FROM CONGRESS
IN DECEMBER.
LEGISLATION WAS SIGNED BY THE
PRESIDENT THAT PROVIDED FUNDING
FOR NCI AND NIH AND OTHER
FEDERAL AGENCIES THROUGH
SEPTEMBER 30th OF THIS YEAR
AND CONGRESS DEMONSTRATED ITS
DEEP CONCERN FOR PEOPLE WITH
CANCER AND STRONG SUPPORT OF OUR
WORK.
WE RECEIVED A TOTAL BUDGET
INCREASE OF $408 MILLION FOR
2023 WHICH WAS $386 MILLION AND
$22 MILLION TO THE FINAL YEAR OF
THE FIRST ROUND OF MOONSHOT
FUNDING FOREL 21st CENTURY
CURES ACT.
WE HAVE RECEIVED A TOTAL OF
$216 MILLION IN CANCER MOONSHOT
FUNDING THAT YEAR.
THIS INCREASE TODAY OUR BICE
MAKES IT POSSIBLE TO FUND MORE
COMPELLING INVESTIGATOR
INITIATED RESEARCH AND TO
CONTINUE TO SUPPORT KEY RESEARCH
OUTSIDE OF THE RPG POOL
INCLUDING OUR CANCER CLINICAL
TRIALS NETWORK, CORE SUPPORT FOR
NCI DESIGNATED CANCER CENTERS,
TRAINING AND THE INTRAMURAL
PROGRAMS.
I'M VERY PLEASED TO SAY THAT
WITH INCREASE WE WERE ABLE TO
INCREASE THE RO1 PAYLINES TO THE
12th PERCENTILE COMPARED TO
11% IN 2022.
WE WERE ALSO NOT ABLE TO
INCREASE THE RO1s TO THE
17th PERCENT UP FROM 16%.
BECAUSE OF THESE PAYLINE
INCREASES WE WERE ABLE TO FUND
MORE THAN 100 ADDITIONAL RO1 AND
ESI AWARDS COMPARED TO LAST
YEAR.
RPG FUNDING IS VERY IMPORTANT.
IT ALLOWS INVESTIGATORS, ACROSS
THE NATION, AND SOMETIMES THE
WORLD, TO SUBMIT THEIR VERY BEST
IDEAS.
AND TURN THEIR INNOVATIVE NEW
IDEAS INTO ANSWERS THAT DRIVE
PROGRESS.
ANOTHER BIG PRIORITY FOR US IS
FUNDING CRITICAL INFRASTRUCTURE,
INCLUDING INFORMATION
TECHNOLOGY.
THESE ARE THINGS THAT PROMISE TO
AMPLIFY CANCER RESEARCH RESULTS,
DRIVE NEW COLLABORATIONS, AND
ENSURE MAXIMAL USE OF OUR PRIOR
COMMENTS AND RESEARCH.
SO WE'VE ALLOCATED NEW FUNDING
TO MEET THESE NEEDS.
UNFORTUNATELY, LIKE SO MUCH OF
BIOMEDICAL RESEARCH, WE HAVEN'T
BEEN IMMUNE TO THIS PERIOD OF
SIGNIFICANT INFLATION.
AS A RESULT, OUR DECISION TO
RAISE PAY LINES AND FUND
CRITICAL INFRASTRUCTURE ALSO
REQUIRES COST-CUTTING ELSEWHERE.
WE DECIDE TODAY PAY MOST
CONTINUING, NON COMPETING GRANTS
THAT IS YEARS TWO THROUGH FIVE
OF A TYPICAL FIVE-YEAR GRANT AT
95%.
WE ALSO CONSIDERABLY TIGHTENED
OUR BELTS AT NCI, RELEVANT TO
THE INTRAMURAL PROGRAM.
AFTER WE COVERED OUR INCREASED
BASELINE COST, WE ALSO HAD OUR
DIVISIONS, OFFICERS, AND CENTERS
TAKE A 2% CUT.
AS JUST AS WE ASKED OUR
EXTRAMURAL RESEARCHERS TO DO.
YOU MAY HAVE SEEN THIS IN OUR
FISCAL YEAR 2024 ANNUAL PLAN AND
IN OUR WEBSITE.
IT SHOWS THE CHALLENGE THAT WE
TAKE ON EVERY TIME WE RAISE THE
PAYLINE.
WHEN WE INCREASE THE PAYLINE
EVERY YEAR, WE MAKE A COMMITMENT
TO SUSTAIN THOSE GRANTS FOR AT
LEAST FIVE YEARS.
SO, WE ALWAYS REQUIRE ADDITIONAL
RESOURCES IN THE OUT YEARS, YEAR
TWO THREE FIVE, JUST TO SUSTAIN
FUNDING AT THAT PERCENTILE
LEVEL.
EVEN MORE, IF WE ARE TO GO ON TO
FURTHER INCREASE THE PAYLINE.
LET ME JUST EMPHASIZE OUR
PAYLINE AT 12% IS NOW THE
HIGHEST IT HAS BEEN SINCE 2010,
A 13 -- IT'S BEEN 13 YEARS SINCE
THE PAYLINE HAS BEEN 12% AND
HIGHER.
SO, I'M SURE I'LL SEE THE
IMPORTANCE OF THIS IN SPITE OF
THE FACT IT INTRODUCES
CHALLENGES FOR THE FUTURE AND IS
ASKED FOR SOME BELT-TIGHTENING
BOTH IN THE EXTRAMURAL AND
INTRAMURAL COMMUNITIES.
I WROTE ABOUT THESE BUDGET
DECISIONS AND CHALLENGE THIS IS
A RESENT POST ON THE NCI
BOTTOMEL LINE BOG WHERE WE
SHARED OUR FISCAL LANDSCAPE,
FUNDING AND PROCESSES.
ON A RECENT NCI CANCER CURRENT
BLOG, I ALSO WROTE A POST THAT
EMPHASIZES THAT THIS IS A TIME
OF GREAT OPPORTUNITY FOR CANCER
RESEARCH BY HIGHLIGHTING
PROGRESS FROM DECADES OF
INVESTMENT.
PRESIDENT JOE BIDEN COMMITMENT
AND IMPORTANT PROGRAMS NCI HAS
LAUNCHED IN THE LAST YEAR.
IN THERE, I ALSO UNDER SCORED
THE IMPORTANCE OF THE LAST MILE.
FROM VALIDATION OF A SUCCESSFUL
INTERVENTION, TO THE BROAD
IMPLEMENTATION.
THIS REQUIRES PARTICIPATION FROM
SO MANY OTHERS THROUGHOUT OUR
SOCIETY.
TO MAKE OUR RESEARCH TRULY
RELEVANT, WE MUST BRIDGE THIS
GAP WHEN A NEW APPROACH IS
IDENTIFIED, TO ENSURE THAT ALL
OF OUR ADVANCES, BENEFIT ALL WHO
NEED THEM.
I BELIEVE STRONGLY IF WE WERE
GOING TO END CANCER AS WE KNOW
IT, IT WILL TAKE AN
ALL-OF-SOCIETY APPROACH.
NCI CANNOT DO THIS ALONE.
IN THIS POST, I ALSO TOUCHED
BRIEFLY ON SOMETHING WE'RE
CALLING THE NATIONAL CANCER
PLAN, WHICH IS AIMED AT THIS
EXACT ISSUE.
AS LEADER OF THIS NATIONAL
CANCER PROGRAM, SOMETHING I AM
CHARGE WITH BASED ON THE
NATIONAL CANCER ACT OF 1971,
WE'VE WORKED WITH RESEARCHERS,
BOTH WITHIN AND OUTSIDE OF NCI
TO PRODUCE SOMETHING WE ARE
CALLING THE NATIONAL CANCER
PLAN.
WHICH IS A PLAN FOR US TO ALIGN
BROAD SOCIETAL ENGAGEMENT AND
FOCUS ON CRITICAL NEEDS TO
ENTITLED CANC END CANCER AS WE W
IT.
THE NATIONAL CANCER PLAN
EMPHASIZES THAT EVERYONE HAS A
ROLE IN MAKING THE BROADEST --
AND ACHIEVING THE BROADEST GOAL
WHICH IS TO HELP PEOPLE WITH
CANCER LIVE FULL AND ACTIVE LIFE
FREE FROM THE EFFECTS OF CANCER
AND THAT MEANS EVERYBODY WITH
CANCER AND EVERY CANCER.
THE PLAN OUTLINES RESENT
PROGRESS AND WHAT IT TAKES TO
SUSTAIN AND ACCELERATE IT AND
WHAT IT WILL TAKE TO ACCELERATE
IT AND EMBRACES THE IDEA THAT
EVERYONE HAS A ROLE TO PLAY OF
ACROSS FEDERAL AGENCIES, AS WELL
AS INDUSTRY, ACADEMIA, ADVOCACY
GROUPS, NON PROFITS, EVEN
CAREGIVERS AND PATIENTS.
OUR INTENT IS THAT WHEN ANY
ORGANIZATION OR PERSON LOOKS AT
THIS PLAN, THEY WILL SEE WHERE
THEY FIT IN AS A CONTRIBUTOR TO
PROGRESS AND THEY WILL ALSO BE
ABLE TO SEE THE FULL PICTURE OF
MANY INTER RELATED ACTIONS
NEEDED TO END CANCER AS WE KNOW
IT.
WE'RE IN A PHASE NOW WHICH WE'RE
GETTING INPUT FROM A WIDE RANGE
OF STAKEHOLDERS ON THIS PLAN
THAT WILL BE FINALIZED AND
COMMUNICATED WIDELY THROUGH THE
PUBLIC.
NEXT SLIDE.
O, NOW SOME UPDANCI'S CENTER FOH
AND THE DIVISION OF CANCER
EPIDEMIOLOGY AND GENETICS
PRODUCE THE RESULTS WE NEED FOR
PROGRESS.
CCR RESEARCHERS HAVE HELPED US
TO BETTER UNDERSTAND, FOR
EXAMPLE, MESA THEME OL A FORM OF
CANCER THAT INVOLVES THE LUNGS
AND LINING OF THE ABDOMINAL
CAVITY, AND IT'S PROVEN VERY
DIFFICULT TO TREAT.
CCR RESEARCHERS HAVE IDENTIFIED
A 48-GENE SIGNATURE IN WHICH
HIGH-EXPRESSION OF CERTAIN GENES
ARE ASSOCIATED WITH WORSE
SURVIVAL IN PLURAL AND PER
TENILLE MESA THEME A OL A AND
ANTI-PD1 THERAPY AND DRUG
COMBINATIONS INVOLVING PEMATRXID
WERE EFFECTIVE FOR TWO OF
SUBSETS OF PATIENTS WITH MESA
FEEL' OWN A N ADDITION A PHASE
CLINICAL TRIAL FROM THE
FREDERICK NATIONAL LABORATORIES
SHOWED LOW-DOSE TEMADOLOMIA AND
TDMI MAY PREVENT BRAIN MATAS
ADVERTISE FOR BREAST CANCER S
83% OF PATIENTS IN THIS STUDY
DEVELOPED NO NEW BRAIN
METASTASIS, A REMARKABLE RESULT
AND WE LOOK FORWARD TO SEEING
THIS VERY IMPORTANT PHASE 1
RESULT MOVING FORWARD.
WE ALL KNOW THAT TRANSGENDER AND
GENDER DIVERSE PEOPLE OFTEN FACE
DISCRIMINATION AND
MARGINALIZATION.
DCEG RESEARCHERS HAVE BEEN
LOOKING INTO THE EFFECTS OF
THIS.
THEY FOUND DATA FROM THE U.K.
THAT TRANSGENDER AND DIVERSE
PEOPLE IN FACT HAVE AN ELEVATED
RISK OF OVER ALL MORTALITY,
COMPARED TO CISGENDER PEOPLE DUE
TO EXTERNAL CAUSES OF DEATH.
SUCH AS SUICIDES, HOMICIDES, AND
ACCIDENTAL POISONING.
AS WELL AS ENDOCRINE DISORDERS
AND OTHER CAUSES.
CONCERNING CANCER MORTALITY,
TRANCE FEMININE INDIVIDUALS
WHICH ARE PEOPLE ASSIGNED MALE
AT BIRTH, HAVE DECREASED RISK OF
DEATH FROM CANCER, COMPARED TO
CISGENDER WOMEN, BUT THE SAME AS
CISGENDER MEN.
TRANS-MASCULINE INDIVIDUALS,
PEOPLE ASSIGNED FEMALE AT BIRTH,
EXPERIENCED OF COMPARABLE RISK
OF DEATH FROM CANCER TO THAT OF
CISGENDER INDIVIDUALS.
CANCER CARE MEANS THAT WE
SUPPORT THE NEEDS OF THE WHOLE
PERSON.
AND THERE'S CLEARLY A NEED TO
DEVELOP INTERVENTIONS SUCH AS
MENTAL HEALTH AND SOCIAL SUPPORT
TO PREVENT SUICIDE AND VIOLENCE
THAT AMONG THESE POPULATIONS.
WE'RE CELEBRATING THE 50th
ANNIVERSARY OF THE SURVEILLANCE
EPIDEMIOLOGY AND END RESULTS
PROGRAM OR CAR.
AS IT PROVIDES INVALUABLE DATA
FROM REGISTRIES THAT COVER
ALMOST HALF OF THE U.S.
POPULATION.
DCEG SHARED A GREAT POST ON ITS
SITE THAT TALKS ABOUT THE
IMPORTANT ROLE THEY PLAY IN MUCH
OF THE RESEARCH.
THROUGHOUT THE REST OF THE YEAR,
YOU WILL SEE A SERIES OF
INFORMATION ON SARS-CoV- CONTRIO
CANCER RESEARCH AND
PUBLIC-HEALTH AS WELL, ON-LINE,
ON SOCIAL MEDIA AND VARIOUS
EVENTS.
FINALLY, I'LL ALSO NOTE THAT
DCEG AND EXPERTS ARE
PARTICIPATING IN THE
INTERNATIONAL PAPILLOMA VIRUS
SOCIETY AN ACTUAL MEETING,
TAKING PLACE IN WASHING NOT TON
D.C. NEXT MONTH.
DOUG LOWY, WHO NEEDS NO
INTRODUCTION, WHEN IT COMES TO
HPV EXPERTS, IS GIVING THE
KEYNOTE ON THE LAST DAY.
NEXT SLIDE, PLEASE.
ANOTHER HIGHLIGHT I'LL SHARE
WITH YOU IS ABOUT THE CANCER
CARE -- CHILDHOOD CANCER DATA
INITIATIVE.
GETTING DATA WE NEEDS TO IMPROVE
OUR UNDERSTANDING OF CANCER.
ESPECIALLY CHILDHOOD CANCER, IS
VERY CHALLENGING AND COSTLY.
THE GOOD NEWS IS, WE'RE MAKING
GREAT HEAD WAY TO GET MUCH
NEEDED CHILDHOOD CANCER DATA
INTO THE HANDS OF SCIENTISTS,
THROUGH CCDI.
THIS FOCUSED PROGRAM HAS MADE
TREMENDOUS PROGRESS TO
ACCUMULATE DATA THAT HAS
HISTORICALLY BEEN VERY
CHALLENGING FOR RESEARCHERS TO
ACCESS.
THIS YEAR, GREG REEMAN HAS TAKEN
CHARGE OF CCDI BRINGING HIS VAST
EXPERIENCE FROM HUSBA HIS TIME G
THE CHILDREN'S ONCOLOGY GROUP
AND WORKING AT FDA.
THE TEAM CONTINUES TO ADD TO
CCDI'S TECHNOLOGICAL
CAPABILITIES WITH NUMEROUS
UPDATES OVER THE LAST SEVERAL
MONTHS THAT MAKE IT EASIER AND
BETTER.
EASIER AND MORE EFFECTIVE FOR
RESEARCHERS TO USE CCDI DATA.
AND FINALLY ON MARCH 24th,
CCDI WILL HOST AN ANNUAL
SYMPOSIUM THAT WILL GATHER
EXPERTS FROM ACROSS THE COUNTRY
TO DISCUSS THE OVER ALL PROJECT
OF THE INITIATIVE, THE NEW
RESOURCES AVAILABLE TO THE BROAD
SCIENTIFIC COMMUNITY AND
OPPORTUNITIES FOR THE FUTURE.
IF YOU CAN, I STRONGLY ENCOURAGE
YOU TO ATTEND, WHICH YOU CAN DO
IN-PERSON OR VIRTUALLY.
EVEN IF YOU ARE NOT A
RESEARCHER, PARTICULARLY
INTERESTED IN CHILDHOOD CANCER,
ATTENDING THIS SYMPOSIUM WILL
ALLOW YOU TO SEE WHAT IS
POSSIBLE I IF WE NOW SCALE EFFOS
SUCH AS CCDI ACROSS OUR ENTIRE
CANCER ECOSYSTEM.
THIS IS ONE OF THE MAIN GOALS OF
NCI OVER ALL.
SO, SOME FINAL THOUGHTS, I'LL
WRAP-UP HERE.
THERE'S A LOT HAPPENING FROM
STEP-BY-STEP SCIENCE WE WON'T
MAKE PROGRESS WITHOUT.
TO HIGH-LEVEL PLANNING TO BEST
LEAD AND ALIGN THE CANCER
RESEARCH ENTERPRISE, TRULY, ALL
OF SOCIETY, AS WE ACHIEVE
PROGRESS EVERYONE IS COUNTING
ON.
WE'RE STILL VERY FAR FROM WHERE
WE NEED TO BE FOR THE MILLIONS
OF PEOPLE OUT THERE STILL FACING
THIS AWFUL DISEASE AND THE MANY
MORE WE HOPE TO PREVENT FROM
EVER HAVING TO DO SO.
BUT I'M REALLY EXCITED ABOUT THE
STEPS RETAKING NOW AND RECENT
ACCOMPLISHMENTS THAT ENSURE
WE'RE ON THE RIGHT PATH.
SO, LET ME END THERE AND GET TO
THE BEST PART OF MY TIME WITH
YOU TODAY.
THAT IS BEING ABLE TO TAKE YOUR
QUESTIONS.
>>THANK YOU, MUCH Dr.
BERTAGNOLLI AND WE OPEN IT UP TO
QUESTIONS NOW.
I BELIEVE Dr. CHUCK RIVARDI
HAS HIS HAND UP.
>>THANK YOU SO MUCH, Dr.
BERTAGNOLLI, FOR YOUR TREMENDOUS
LEADERSHIP.
I THINK WE'RE ALL VERY EXCITED
ABOUT WHAT THE FUTURE HOLDS FOR
THE NCI UNDER YOUR RELATIONSHIP.
SO, THANK YOU.
I JUST HAD SEVERAL QUICK
QUESTIONS.
THE FIRST BEING PRESIDENT JOE
BIDEN'S ROLLOUT OF THE ARPA-H
PROGRAM AND HOW IT DOVE TAILS
WITH THE NIH OVER ALL MISSION?
WHERE DID IT BEGIN AND END AND
SO FOURTH?
>>Dr. Bertagnolli: GREAT
QUESTION.
SO, FIRST OF ALL, RENEE WAGERSON
AND THE NEW ARPA-H DIRECTOR AND
I ARE IN FREQUENT
COMMUNICATIONS.
WE TALK EVERY OTHER WEEK.
WHY ARE WE DOING THAT?
IT'S BECAUSE WE'RE WORKING
TOGETHER TO DECIDE HOW ARPA-H
AND NCI CAN HAVE THE MOST
POWERFUL COLLABORATION.
THE IDEA IS THIS -- IN GENERAL,
NCI HAS TO TAKE THE VERY LONG
VIEW.
WE ARE RESPONSIBLE FOR
EVERYTHING FROM BASIC,
FUNDAMENTAL SCIENCE, BASIC
DISCOVERY, ALL THE WAY TO CANCER
CARE DELIVERY RESEARCH THAT
MAKES SURE THAT A RESULT, TAKEN
ALL THE WAY FROM THE LAB THROUGH
CLINICAL TRIALS, GETS TO THE
PATIENTS WHO REALLY NEED IT.
THE HAVE LONG AND VERY
BROADVIEW.
VERY LONG BROAD.IT TAKES YEARS D
THAT'S THE VIEW WE HAVE TO HAVE.
ARPA-H'S FOCUS IS DIFFERENT.
IT IS DESIGNED TO IDENTIFY
PARTICULAR KEY QUESTIONS -- KEY
PROBLEMS, THAT ARE AMENABLE TO
HIGH-RISK, HIGH REWARD, RESEARCH
FOCUS.
THEY PICK THESE AND PROVIDE A
REALLY INTENSE, ACROSS THE
BOARD, STRATEGY TO SOLVING THEM.
I'LL GIVE YOU AN EXAMPLE.
THIS IS ONE THAT WE'VE DEVELOPED
TOGETHER WITH Dr. WAGERSON AND
I KNOW WE WILL BE COLLABORATING
WITH ARPA-H ON.
ONE OF THE THINGS WE NEED TO DO
TODAY IS TO BE ABLE TO INTEGRATE
PATHOLOGY, CLINICAL PATHOLOGY,
THE IMAGES THAT COME OFF OF H
AND E SLIDES WITH ALL OF THE
COMPLEX WAYS THAT WE INTERROGATE
A TIME OR.
PROTEOMICS, GENOMICS, SINGLE
CELL, SINGLE CELL TRANCE TRANSCT
OMICS, ET CETERA.
WE HAVE TO PROVIDE THAT DATA IN
A FORMAT THAT ALLOWS
PATHOLOGISTS TO ACHIEVED BETTER
DIAGNOSIS AND CLINICIAN TO
ACHIEVE BETTER TARGETED
TREATMENTS.
WE DON'T HAVE THE SYSTEMS RIGHT
NOW THE TECHNOLOGY, THE
SOFTWARE, TO PULL ALL OF THOSE
DISPARATE DATA STREAMS TOGETHER.
THAT'S A PERFECT ARPA-H PROJECT.
WE ARE PLANNING FOR THIS
INTEGRATED PATHOLOGY AND IMAGING
APPROACH TO BE DEVELOPED AND IT
WILL PROBABLY INVOLVE MULTIPLE
PARTNERS, MULTIPLE DIFFERENT
EFFORTS AND NCI RESEARCHERS WHO
NEED TO TAKE THIS NEW PRODUCT
AND USE IT FOR OUR OWN RESEARCH
AND TRANSLATION TO CLINICAL
CARE, WILL BE AT THE ELBOW OF
THOSE IN ARPA-H H DEVELOPING
THESE SO IT'S A NEW WAY OF
THINKING OF THINGS, I GUESS IN
THE OLD DAYS, WE MIGHT DEVELOP A
NEW FOCUS FOR SOMETHING LIKE
THIS WITHIN NCI SOMEWHERE, BUT
BOY IT'S A TREMENDOUS BENEFIT TO
ALL OF US TO HAVE THIS NEW
ENTITY, THIS NEW FUNDING, AND
THIS NEW ENTHUSIASM TO DO WORK
LIKE THIS IF WE CAN BE CLOSE
PARTNERS.
>>Dr. BERTAGNOLLI, JUST TO
FOLLOW-UP, SO WITHIN THE OS
PISISTHERE HIGH REWARD AND HIGHK
TYPE OF RESEARCH VERSUS THE MORE
TRADITIONAL HYPOTHESIS RESEARCH
AND WHAT ARE THE UNIQUE ASPECTS
OF THE INTRAMURAL PROGRAM IS
THAT IN THAT A LOT OF THE
PROJECTS ARE AMBITION AND OUT OF
THE BOX IN THINKING.
SO AS REVIEWERS, SHOULD WE
CONTINUE TO REWARD CUTTING THE
HIGH-RISK HIGH-REWARD TYPE OF
ENDEAVOR WITHIN THE INTRAMURAL
PROGRAM?
THANK YOU.
>>Dr. Bertagnolli: ABSOLUTELY.
LOOK, WE NEED BALANCE.
WE NEED BALANCE IN WHAT WE DO.
WE CAN'T IGNORE THE BENEFITS
THAT CAN COME WHEN YOU GET THE
BRASS RING IN A HIGH-RISK HIGH
REWARD ENDEAVOR AND I THINK YOU
ARE ALL VERY WISE IN ENCOURAGING
THAT, ENCOURAGING THAT THAT KIND
OF RESEARCH HAS A HOME AT NCI.
ALSO, WE CAN'T FORGET, THAT
STEADY INCREMENTAL PROGRESS HAS
ACHIEVED TREMENDOUS BENEFITS IF
OUR PATIENTS.
YOU KNOW, THAT IS NOT TO BE
UNDER APPRECIATED OR UNDER
RESOURCED.
SO, IT'S ALWAYS ABOUT THE
BALANCE AND THIS IS WHY WE'RE
GRATEFUL FOR YOUR ADVICE AND
YOUR INPUT BECAUSE YOU ARE
CRITICAL TO HELPING US ACHIEVE
THAT BALANCE.
>>ANYBODY ELSE ON THE BOARD
WITH A QUESTION?
I CAN JUMP IN.
I WAS VERY INTRIGUED BY THE
NATIONAL CANCER PLAN THAT YOU
ARE CURRENTLY FORMULATEING AND
WHAT I'M CURIOUS TO HEAR YOUR
THOUGHTS ABOUT IS IN TERMS OF
THE GOAL OF LINING BROAD
SOCIETAL ENGAGEMENT, WHERE IS
THAT INTO EVINEED GREATEST?
HOW ARE YOU PRIORITIZING SO MANY
THINGS THAT FALL UNDER THAT
PARTICULAR --
>>SO WHAT YOU ARE GOING TO SEE
IN THE NATIONAL CANCER PLAN ARE
EIGHT MAJOR GOALS.
AND NONE OF THESE GOALS ARE
GOING TO BE A SURPRISE TO YOU.
YOU KNOW, THEY ARE ARE THINGS
LIKE -- THEY ARE ALONG THE
THEMES OF CA CANCER PREVENTION,
EARLY DETECTION, ELIMINATING
DISPARITIES, MAINTAINING AND
GROWING AND NURTURING OUR
WORKFORCE FROM SCIENCE ALL THE
WAY THROUGH CARE DELIVERY.
ENSURING DELIVERY OF BEST CARE,
ET CETERA.
YOU ARE GOING TO RECEIVE THE
THINGS YOU KNOW ARE CRITICAL TO
SUCCESS IN ELIMINATING SUFFERING
FOR CANCER.
YOU ARE ALSO GOING TO SEE, I
BELIEVE, THAT EACH OF THESE
OBJECTIVES REQUIRE FAR BEYOND
WHAT NCI ALONE CAN DO.
SO, PART OF THE PLAN IS UNDER
EACH OF THE EAST MAJOR AREAS,
EIGHT MAJOR GOALS WE NEED TO BE
ACHIEVED, YOU WILL SEE A
DESCRIPTION TARGETED
DESCRIPTION, OF WHERE NCI IS
MAKING A MAJOR CONTRIBUTION.
AT THE END, YOU WILL SEE OF A
CALL FOR THE REST OF SOCIETY TO
PARTICIPATE.
SO A QUICK EXAMPLE, PREVENT
CANCER.
OKAY.
OBVIOUSLY YOU KNOW, PROBABLY OUR
MOST IMPORTANT GOAL IN REALLY
HAVING AN IMPACT.
SO, AT NCI, WE CAN DO MORE
FUNDAMENTAL RESEARCH TO
UNDERSTAND EXACTLY WHAT CAUSES
CANCERS, YOU KNOW, SO WE CAN
UNDERSTAND HOW TO INTERVENE AT
THE EARLIEST POINT AND WE CAN
THEN DEPLOY STRATEGIES THAT
LEADS TO EFFECTIVE CANCER
PREVENTION, BUT WHAT WE CAN'T DO
AND WE CAN STUDY THE THINGS THAT
INHIBIT THE PROCESS OF CANCER
BEING PREVENTED.
LIKE, WHAT IS PREVENTING PEOPLE
FROM SMOKING CESSATION?
WHAT ARE THE APPROPRIATE WAYS TO
MAKE SURE THAT UNDER REPRESENTED
POPULATIONS OR POPULATIONS THAT
HAVE HEALTH DISPARITY REALLY
ACHIEVE THE EDUCATION AND
SUPPORT THAT THEY NEED TO
DEVELOP LIFESTYLE FACTORS THAT
WOULD REDUCE CANCER.
AGAIN, PREVENT CANCER HAS WITHIN
IT, GOALS THAT GO FROM BASIC
FUNDAMENTAL SCIENCE ALL THE WAY
THROUGH CARE DELIVERY SO EACH OF
THESE GOALS IS VERY BROAD.
AND AT THE END OF THE DAY, NCI
RESEARCH WON'T DO IT ALONE.
THERE'S A LOT OF THINGS THAT
WOULD HAVE TREMENDOUS IMPACT ON
CANCER PREVENTION.
NEW TOBACCO REGULATION THAT FDA
IS PULLING FORWARD WOULD BE A
TREMENDOUS HELP FOR INSTANCE, SO
FDA WOULD HAVE A MAJOR ROLE TO
PLAY THAT LEGISLATION GOES
THROUGH AND NEW -- AND THEN
RIGHT DOWN TO THE INDIVIDUAL
PATIENT LEVEL.
YOU KNOW, INDIVIDUAL PEOPLE
DOING THEIR PART TO STAY OUT OF
THE SUN, STOP SMOKING, VERY
SIMPLE THINGS SO I THINK THAT
THE POINT WE'RE TRYING TO MAKE
IS NCI CAN DO A TREMENDOUS
AMOUNT BUT IF WE'RE REALLY GOING
TO CO CONQUER THIS DISEASE WE ND
EVERYBODY TO PARTICIPATE.
THAT'S A LITTLE BIT DIFFERENT
THAN WHAT YOU USUALLY SEE WHEN
WHEN WE PUT OUT A CALL FOR
ACTION IN CANCER.
>>THANK YOU.
WE'RE JUST ABOUT OUT OF TIME.
ARE THERE ANY LAST QUESTIONS
FROM THE BOARD?
IF NOT, LET ME ON BEHALF OF MY
CO-CHAIR PAT LORUSSO AND THE
BOARD, THANK YOU FOR YOUR
PRESENTATION.
>>Dr. Bertagnolli: IT'S GREAT
TO SEE YOU ALL.
THANK YOU FOR BEING HERE.
>>THANK YOU.
AND I BELIEVE NOW WE NEED TO SIT
TIGHT WHILE AV WILL SINUS OFF
FROM THE VIDEO CAST SYSTEM.
THE GOAL IS THAT WE DON'T HAVE
TO RECONNECT BUT WE'LL SEE
WHETHER IT WORKS.
>>IF YOU GET DISCONNECTED, JUST
CALL RIGHT BACK IN.
>>YES.
>>AND WE'LL TAKE ABOUT A --
WE'LL RECONVENE AT 11:40 THAT
SHOULD GIVE TIME TO DISCONNECT
AND TAKE A BREAK.
>>OKAY.
THANK YOU.